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Although biotherapeutics have vast potential for
treating brain disorders, their use has been limited
due to low exposure across the blood-brain barrier
(BBB). We report that by manipulating the binding
mode of an antibody fragment to the transferrin
receptor (TfR), we have developed a Brain Shuttle
module, which can be engineered into a standard
therapeutic antibody for successful BBB trans-
cytosis. Brain Shuttle version of an anti-Ab antibody,
which uses a monovalent binding mode to the TfR,
increases b-Amyloid target engagement in a mouse
model of Alzheimer’s disease by 55-fold compared
to the parent antibody. We provide in vitro and in vivo
evidence that the monovalent binding mode facili-
tates transcellular transport, whereas a bivalent
binding mode leads to lysosome sorting. Enhanced
target engagement of the Brain Shuttlemodule trans-
lates into a significant improvement in amyloid
reduction. These findings have major implications
for the development of biologics-based treatment
of brain disorders.
INTRODUCTION
A major challenge to the development of biologics-based thera-
peutics is the inability of large molecules to effectively cross the
blood-brain barrier (BBB). This poses a substantial risk to the
effective development of protein and antibody-based therapies
for brain disorders. For example, many of the leading therapies
being developed for Alzheimer’s disease rely on antibodies
that target the b-amyloid protein, but only around 0.1%–0.2%
of the antibody crosses into the brain (Poduslo et al., 1994).
Developing effective strategies to transport large molecules
across the BBB has been a long-standing goal of the field, which
could transform the development of biotherapeutics for neuro-
logical and psychiatric disorders.
An attractive target for developing strategies to move mole-
cules across the BBB has been the transferrin receptor (TfR)(Pardridge, 2012; Wang et al., 2013; Pardridge and Boado,
2012), which mediates receptor-mediated transcytosis (RMT).
It has been shown that either modulating the affinity of anti-TfR
antibodies or using a peptide as a transferrin ligand can improve
brain exposure (Yu et al., 2011; Staquicini et al., 2011), although
the increase in brain penetration is modest. We sought to inves-
tigate whether we could design a molecular shuttle (Brain Shut-
tle) that would effectively engage the transcytosis mechanism to
enhance transport of therapeutic antibodies across the BBB and
thereby achieve increased potency. We hypothesized that biva-
lent engagement of the TfR, as has commonly been explored,
might interfere with the normal transcytosis of cargos and that
monovalent binding to the receptor might engage the sorting
pathway normally used to transport monomeric transferrin and
lead to more efficient transport across brain endothelial cells
(BECs).
We present evidence that indeed amolecular shuttle that uses
monovalent binding to the TfR leads to successful transcytosis
and increases brain exposure of a therapeutic antibody by well
over an order of magnitude.We also provide in vivo data showing
that transcellular transport occurs via vesicular structures inside
the BECs. Using both mouse and human in vitro model systems,
we show that bivalent binding to TfR induces lysosomal sorting
and degradation consistent with the incomplete transcellular
trafficking observed in vivo. In addition, bivalent receptor binding
leads to a gradual downregulation of cell surface TfR because
recycling of endocytosed TfR is prevented. Finally, we confirm
the therapeutic potential of our approach by showing significant
reduction in amyloid load in a mouse model of Alzheimer’s
disease.
RESULTS
Engineering of the Brain Shuttle Constructs
To test the hypothesis that mode of binding to the TfR would
affect transcytosis, we engineered two different types of Brain
Shuttle constructs with a single-chain (sc) Fab fragment of an
anti-TfR monoclonal antibody (mAb) fused either to one or
both C-terminal ends of the heavy chain of an anti-Ab mAb
(mAb31). Thus, the Fab fragment was introduced either as a
single (sFab) or double (dFab) format (Figure 1A). The mAb31
used in the present study as a cargo has been shown toNeuron 81, 49–60, January 8, 2014 ª2014 Elsevier Inc. 49
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Figure 1. Schematic Representation of the
Anti-Ab mAb, Brain Shuttle Constructs,
and the Antigen Binding Properties
(A) The Fab fragment (red/magenta) that binds the
TfR is fused to the Fc region (gray) at the
C-terminal end of an anti-Ab mAb (mAb31) and
contains either two (dFab) or one (sFab) Fab
fragment. The sFab construct is produced using
the knobs-into-holes approach (light- and dark-
gray Fc).
(B) Indirect ELISA shows apparent affinity to TfR at
two different coating densities (1 mg/ml mTfR solid;
0.5 mg/ml mTfR stippled) for the original anti-TfR
IgG format and the two Brain Shuttle constructs.
The sFab shows a slight reduction in apparent
affinity compared to dFab (5.3- to 8.9-fold
dependent on coating density) due to loss in
avidity.
(C) ELISA displays the apparent binding affinity to
immobilized b-amyloid fibrils of the parent mAb31,
dFab, and sFab constructs. All constructs show
comparable high-affinity binding (between 0.25
and 0.09 nM).
(D–G) Cryosections from 12-month-old PS2APP
transgenic mice were stained with the following
constructs: (D) control using only the secondary
detection antibody, (E) mAb31, (F) sFab, and (G)
dFab. All constructs bind equally well to b-amyloid
plaques in PS2APP transgenic animals. CTL,
control where no antibody construct has been
added to check for background signal.
Data are presented as mean ± SD. See also
Figure S1.
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Receptor Binding Mode Dictates BBB Crossingspecifically bind with high affinity to b-amyloid plaques (Bohr-
mann et al., 2012). The sFab format was produced to mimic
the monovalent binding mode of the natural ligand transferrin,
and the dFab represents a standard IgG configuration, whereas
flexible linkers were used instead of the IgG-hinge regions.
Importantly, none of the Brain Shuttle constructs competes
with the binding of transferrin to the TfR (Figure S1 available
online). The antigen affinity of the constructs was measured in
an ELISA setup against mouse TfR (mTfR) and human Ab pep-
tide. The binding properties toward the TfR were preserved in
the two Brain Shuttle constructs. As expected, the sFab
apparent binding affinity was slightly reduced (5.3- to 8.9-fold)
when compared to the dFab construct and was dependent on
TfR-coating density (Figure 1B). The Ab apparent binding prop-
erties were also preserved in the two Brain Shuttle constructs
showing subnanomolar binding as the parent antibody mAb31
(Figure 1C). In addition, plaque binding on brain tissues from
PS2APP transgenic animals was also maintained (Figures 1D–
1G). Epitope mapping of the anti-TfR mAb (Figure S1) shows
that the Brain Shuttle module binds at the apical domain of
TfR, which is distant to the binding site of transferrin.
Receptor Binding Mode Determines TfR Cellular
Trafficking within BECs
We used a BEC system (bEnd3 cells) to investigate the intracel-
lular sorting of the sFab and dFab constructs. Previous studies
by Lesley et al. (1989) and Cre´pin et al. (2010) had indicated
that expression and intracellular sorting of TfR were directly50 Neuron 81, 49–60, January 8, 2014 ª2014 Elsevier Inc.affected by valency of the ligand. We exposed BECs with sFab
or dFab at equal concentration for 1 hr to allow TfR binding,
internalization, and intracellular sorting. FACS analysis indicated
that the dFab construct wasmore rapidly internalized (Figure 2A),
and this was confirmed by immunocytochemistry (Figures 2B–
2D). Notably, the high level of colocalization of the dFab
construct with the lysosome-associated membrane protein
Lamp2 suggests significant intracellular sorting of the dFab
construct to the lysosome (Figure 2E). We found that >50% of
vesicular structures positive for Lamp2 also contained the
dFab construct. In contrast to the dFab construct, significantly
less lysosomal colocalization was seen for the sFab construct,
suggesting that the mode of binding to TfR affected intracellular
sorting.
To determine if there was a difference in the rate at which the
sFab and dFab constructs were recycled to the surface, we
treated cells with bafilomycin A1 (BafA1), which is known to
inhibit recycling of transferrin (Michel et al., 2013; Kozik et al.,
2013). BafA1 treatment led to a strong increase in cellular accu-
mulation of the sFab (Figure S2), indicating that the sFab
construct is normally recycled back to the cell surface, whereas
the dFab construct showed defective recycling even without
BafA1 treatment. If the bivalent receptor binding mode of the
dFab construct induces sorting of the construct to the lysosome,
one would expect that cellular TfR levels would be affected when
exposed to dFab. Consistent with this prediction, exposure of
the BECs to the dFab construct significantly decreased cell sur-
face TfR to almost nondetectable levels (Figure 2F). In contrast,
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Receptor Binding Mode Dictates BBB Crossingthe sFab construct had no detectable effect on cell surface
expression levels of TfR (Figure 2F), indicating that the monova-
lent binding mode of sFab does not disturb the cellular TfR
homeostasis. We also performed intra- and extracellular staining
of TfR using FACS. Again, we observed downregulation of cell
surface TfR at an early time point, but the total cell TfR was not
affected (Figure 2G). However, after 24 hr exposure to the
dFab construct, the internalized fraction of TfR was no longer
detectable, likely due to lysosomal degradation. dFab-induced
degradation of the TfR was confirmed by analyzing protein levels
using western blot (Figure S3).
We sought to confirm our observations in a BBB transcytosis
assay using the well-characterized human BEC line hCMEC/D3
(Weksler et al., 2005). Because the anti-TfR Fab fragment used
in the experiments described above is not cross-reactive with
human TfR, mono- and bivalent antibody constructs binding to
human TfR were generated and tested in a standard transwell
setup (Figure 2H). Because hCMEC/D3 cells are known to form
leaky tight junctions (Weksler et al., 2005), the assay was per-
formed in a pulse-chase mode to avoid assay disturbance by
paracellular flux. The monovalent (Figure 2I) or bivalent (Fig-
ure 2J) antibodies were added in the upper chamber to allow
internalization promoted by the TfR expressed on the apical sur-
face of the hCMEC/D3 cells. After receptor-mediated uptake for
1 hr, the upper and lower chambers were washed, and the
amount of construct in the upper and lower chambers as well
as inside the BECs was quantified over time. Only the monova-
lent antibody could be detected in the lower chamber, whereas
the bivalent antibody was not detected. These experiments, us-
ing a different mono-/bivalent TfR antibody pair with specificity
for human TfR, confirm our previous findings in a murine system
and indicate that receptor bindingmode determines efficiency of
transcytosis. Importantly, the monovalent TfR antibody specific
for human TfR, which shows transcytosis activity, has compara-
ble apparent affinity (EC50, 3.8 nM) to the dFab construct (EC50,
6.4 nM), which is incapable of crossing the BBB (both EC50
values determined by FACS). This suggests that the monovalent
binding mode to the TfR, and not just reduced affinity, is the key
factor for efficient transcytosis. Interestingly, this human-
specific antibody binds to a similar region on the apical domain
of the TfR as the mouse-specific antibody (Figure S1).
In the next series of experiments, we wanted to determine if
the sFab and dFab constructs behave differently when engaging
with the TfR on the BBB in vivo. To investigate the transport pro-
cess, we used the well-characterized PS2APP double-trans-
genic mouse model of amyloidosis (Richards et al., 2003) in
which the quantification of amyloid plaque-bound mAb31
enabled us to directly measure target occupancy in the brain.
We first studied the rate of BBB crossing shortly after injection
of equimolar amounts of the two Brain Shuttle constructs. At
15 min after intravenous (i.v.) injection, there was a substantial
uptake into brain microvessels of both the sFab and dFab con-
structs (Figures 3A, 3B, and 3F). However, at 8 hr postinjection,
we observed a striking difference in the distributions of the sFab
and dFab constructs.Whereas the sFab construct concentration
was significantly reduced in the capillaries and highly associated
with amyloid plaques (Figure 3C; higher magnification shown in
Figure 3G), the dFab construct was only detectable within themicrovascular structures (Figure 3D), suggesting that the sFab
construct was more efficient in crossing from the blood vessels
to the brain parenchyma. Quantification of these data confirmed
that reduction of construct localization in themicrovessels corre-
lates with an increase in plaque decoration for sFab due to the
extensive transport of the construct into the CNS compartment
(Figures 3E and 3G). Taken together, these data suggest that
the TfR binding mode of the constructs determines the rate
and extent of transcytosis and thus the degree of brain exposure.
These imaging data, where we detect the construct using fluo-
rescence intensity, were confirmed bymeasuring the concentra-
tion of the constructs in total brain and brain blood vessels in
both transgenic and wild-type animals (Figure S4). Again, we
detected much higher levels of the sFab in total brain compared
to dFab and much more dFab accumulation in the capillary frac-
tion. The data are very similar in both transgenic and wild-type
animals except that the sFab concentration is higher in trans-
genic animals than the wild-type 24 hr postinjection. This
sustained concentration for sFab in transgenic animals could
be due to the intensive target engagement seen using the imag-
ing approach.
To further investigate how the mode of receptor binding
affects sorting of constructs in vivo, we used high-resolution
confocal imaging to elucidate the difference between the sFab
and dFab construct behavior at the BBB. Specific markers for
the luminal side (podocalyxin) and abluminal side (collagen IV)
(Figure 4A) of the microvessels were used to identify the BEC
intracellular space (arrow in Figure 4B). Within 15 min postinjec-
tion, the sFab construct could be identified in granular structures
inside the BECs (Figure 4C; Movie S1). One possibility is that
these granular structures containing the sFab construct are
TfR-containing early endosomes formed by clathrin-mediated
endocytosis. Furthermore, by analyzing microvessel cross-sec-
tions, we were able to identify the sFab and dFab constructs
internalized into the BECs based on costaining with the luminal
marker podocalyxin (Figures 4D and 4F). By 8 hr postinjection,
the staining for sFab construct was reduced, whereas substan-
tial staining was still observed for the dFab construct (Figures
4E and 4G). These data are in agreement with the microvessel
quantification data (Figure 3G).We also investigated the localiza-
tion of sFab and dFab constructs in relation to the abluminal side
by costaining with collagen IV 8 hr postinjection. For the sFab
construct, there was a clear overlap with the abluminal marker
and frequent staining signals in the brain reflecting binding to
parenchymal amyloid deposits (Figures 4H–4K). In contrast,
the dFab staining was only detected inside the BECs and not
in direct contact with the abluminal side (Figures 4L–4O). This
is in agreement with earlier studies showing no or only minor
colocalization of an anti-TfR antibody with laminin (Gosk et al.,
2004) and collagen IV after i.v. injection (Paris-Robidas et al.,
2011). Thus, the failure of dFab constructs to cross the BBB is
associated with their inability to reach the abluminal side for
a productive release. Costaining with a lysosomal marker
(Lamp2) indicated that the dFab construct was present in lyso-
somal compartments in vivo (Figure 4P). By analyzing the inten-
sity profiles corresponding to dFab and Lamp2 signals, we found
perfect colocalization and that the dFab granule of 350 nm in






Figure 2. Influence on TfR Intracellular Sorting, Cellular Trafficking, and Transcytosis Activity in BECs
(A) Uptake of sFab (green) and dFab (red) by intracellular FACS is presented. MFI, mean fluorescence intensity.
(B–D) Immunocytochemistry on bEnd3 cells for control (B), sFab (C), and dFab (D) constructs is shown in red and lysosomes (Lamp2) in green.
(E) Percentage of lysosomal colocalization after 1 hr uptake is shown.More than 50%of lysosomes contain dFab, whereas less than 20%contain sFab construct.
CTL, control where no antibody construct has been added to check for background signal.
(F) Time- and dose-dependent downregulation of cell surface TfR by dFab at 2.5 mg/ml (red) and 25 mg/ml (pink) is shown. For the sFab construct at 2.5 mg/ml
(green), no significant changes were detected.
(G) Extracellular (red) and total (blue) TfR expression after 1 hr exposure to 2.5 mg/ml dFab leads to cell surface downregulation, but total cell receptor expression
is unaffected. After 24 hr exposure to 2.5 mg/ml dFab, further downregulation of cell surface TfR expression and also intracellular reduction are shown. Isotype
control and nontreated cells (black) are shown in comparison.
(legend continued on next page)
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Figure 3. Brain Microvessel Targeting and
Parenchymal Exposure of dFab and sFab
Constructs in the PS2APP Transgenic
Mouse Model
PS2APP animals treated with equimolar concen-
trations of dFab (16.7 mg/kg) and sFab (13.3 mg/
kg) were perfused, fixed, and processed for
immunostaining.
(A and B) Extensive accumulation of both sFab (A)
and dFab (B) inside BECs 15 min postinjection is
shown.
(C and D) Eight hours postinjection, the sFab (C)
escapes the microvessels into the parenchyma
space and decorates b-amyloid plaques (arrows).
dFab at 8 hr postinjection (D) remains in the
microvessels, and no b-amyloid plaque deco-
ration is detectable. Confocal settings from
the dFab 8 hr sample were used for all images in
(A)–(D).
(E) The amount of sFab and dFab was quantified
by fluorescence intensity within well-defined brain
microvessels.
(F) Quantification shows that both constructs
accumulate rapidly (dFab somewhat faster) within
the BECs, but only the sFab construct is able
to escape the microvessels 8 hr postinjection.
*p% 0.05.
(G) A magnified image shows an amyloid plaque
structure decorated with sFab 8 hr postinjection
(arrow) and the capillaries (arrowheads). Asterisks
indicate the BEC nucleus.
Data are presented as mean ± SD.
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culture findings and indicate that dFab constructs are targeted
for lysosomal degradation, which is likely the reason for the
lack of transcytosis.
Monovalent Receptor Binding Mode Is Crucial for
Transporting Cargo across the BBB
The anti-AbmAb mAb31 is a very specific and potent Ab plaque
binder (Bohrmann et al., 2012), providing us with a powerful
readout to quantify target engagement within brain parenchyma.
We used the PS2APP double-transgenic amyloidosis model
(Richards et al., 2003) to investigate the amount of brain expo-
sure of the two Brain Shuttle constructs compared to the
mAb31 parent antibody. The three variants were injected i.v. at
equimolar concentrations, and the degree of brain exposure
was determined by quantifying the amount of antibody present
at plaques 8 hr postinjection. For the dFab construct, no signifi-
cant increase in plaque decoration was detected compared to
mAb31 (Figure 5A). However, for the sFab construct, there was
a massive increase in plaque decoration in comparison with
the parent mAb31 antibody. These data are in agreement(H) Transcytosis activity of mono- and bivalent antibody constructs against huma
was determined at the luminal side (magenta), abluminal side (yellow), and intrac
(I and J) The monovalent IgG construct was transported to the abluminal side (I, y
side (J).
Data are presented as mean ± SD. *p% 0.05, **p% 0.01, and ***p% 0.001. ns,when directly measuring the concentration of the constructs
with an immunoassay (Figure S4). Target engagement at the
amyloid plaques was improved more than 50-fold for the sFab
construct based on fluorescence intensity quantification using
a labeled secondary antibody. Whereas the sFab construct
showed extensive plaque decoration (Figure 5D), the dFab was
only detectable in the microvessels (Figure 5C), indicating that
the dFab construct targets and enters brain microvessels but
fails to escape at the abluminal side. The sFab construct does
not disrupt the BBB as a mechanism for antibody uptake into
the brain because there was no significant increase in Evans
blue leakage when animals were dosed with the sFab construct
(Figure S6).
We investigated the target engagement capacity of the sFab
construct at a low dose of 2.66 mg/kg and prolonged in vivo
exposure time up to 7 days. Maximal plaque decoration was
reached within 8 hr, followed by persistent plaque binding over
at least 1 week after a single injection (Figure 5E). In a previous
study, the parent mAb31 had been shown to reach maximal
plaque binding 7 days after injection (Bohrmann et al., 2012).
Quantification of the staining in microvessel structures indicatedn TfR was measured in vitro using human BECs. The construct concentration
ellular space (blue).
ellow), whereas the bivalent IgG construct was not detectable at the abluminal
not significant. See also Figures S2 and S3.
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Receptor Binding Mode Dictates BBB Crossingthat the localization of the sFab construct was very transient at
the BBB, illustrating the relatively rapid rate at which the
construct crosses the barrier (data not shown). The representa-
tive plaque-staining images for the parent antibody mAb31 at
2 mg/kg 7 days postinjection (Figure 5F) and equimolar concen-
tration for the sFab construct (Figure 5G) illustrate the increase in
plaque binding one achieves with the sFab Brain Shuttle
construct. The sFab construct shows only a minor colocalization
with the lysosomal compartment, which likely reflects normal
constitutive trafficking of the TfR to the lysosome (Matsui et al.,
2011). Our in vitro studies also showed recycling and trans-
cytosis of the sFab construct. Taken together, these findings
suggest that the sFab construct does not interfere with the
normal trafficking of the TfR. In contrast, the dFab construct
shows strong colocalization with the lysosomal compartment
but no transcytosis activity, neither in vitro nor in vivo. These
findings are captured in a simplified model (Figure 5H), which
illustrates the difference in intracellular trafficking inside the
BECs between sFab and dFab constructs and its comparison
with the natural ligand transferrin.
Increased Antibody Delivery across the BBB Translates
into Enhanced In Vivo Potency
In the final set of experiments, we asked whether the significant
increase in brain exposure using a monovalent binding mode
improves in vivo potency of the anti-Ab antibody in a long-term
treatment study. Because there is no detectable plaque target
engagement of the dFab (Figure S7) even at a high dose
(17.44 mg/kg) 7 days postinjection, we did not include this
construct in further in vivo potency investigations. The sFab
construct was compared to the parent mAb31 antibody, which
shows some target engagement at the equimolar dose level
(10 mg/kg). For this experiment, we injected the sFab construct
and the control parent antibody mAb31 weekly for 3 months. In a
previous 5-month study, the therapeutic antibody mAb31 had
been shown to reduce the plaque burden at 20 mg/kg (Bohr-
mann et al., 2012). Based on the data shown in Figure 5, we
selected two low doses to investigate if improved brain exposure
would lead to enhanced in vivo potency. Target plaque binding at
the end indicated that at both doses, there was stronger target
engagement with the sFab construct than the parent mAb31
antibody (Figures 6A–6D). The degree of amyloidosis in the
APPPS2 double-transgenic mice was quantified at baseline,Figure 4. High-Resolution Imaging of Brain Microvascular Structure Id
PS2APP animals were treated with the constructs as described in Figure 3.
(A) 3D reconstruction of a microvessel using antibodies rise against the lumina
microvessel. The nucleus of the endothelial cell is depicted in blue (DAPI). Dashe
(B) Cross-section of the image displayed in (A) is shown where the arrow indicat
(C) A microvessel with the luminal side (podocalyxin, green) and the sFab const
inside the BECs, clearly illustrated in Movie S1.
(D–G) Subcellular localization of sFab (D and E) and dFab (F andG) inmicrovessel 1
with the same confocal settings. Construct is shown in red and the luminal mem
(H–K) sFab (red) crosses the basal lamina (collagen IV,magenta) of themicrovesse
and sFab-positive plaques around the microvessel (arrowhead).
(L–O) dFab (red) does not reach the abluminal side (collagen IV, magenta) 8 hr p
(P) dFab (red) colocalized with Lamp2-positive lysosomes (green), suggesting sort
the dFab construct (red) accumulates within a Lamp2-positive lysosome (green)
See also Figure S5.and following vehicle, low-dose parent mAb31 and low-dose
sFab construct treatment (Figures 6E–6H). At these low doses,
no in vivo effect was detected with the parent mAb31 (Figure 6I),
which was anticipated based on a previous long-term study over
5 months (Bohrmann et al., 2012). In contrast, a significant
reduction in plaque numbers both in cortex and hippocampus
was observed with the middose of 2.67 mg/kg of the sFab
construct. Even at themuch lower dose of 0.53mg/kg (Figure 6I),
a trend was seen in favor of the sFab construct, especially in the
cortex, although it did not reach statistical significance. A
secondary analysis of plaque sizes revealed a more pronounced
reduction of numbers for small plaques (Figure S8), in agreement
with the mode of action for mAb31 (Bohrmann et al., 2012).
These data indicate that increased brain penetration, enabled
by a monovalent mode of TfR binding, leads to a significant
improvement in the potency of a therapeutic antibody in a
chronic animal model of Alzheimer’s disease pathology.
DISCUSSION
Engagement of the TfR has been used in previous studies as an
approach to facilitate the movement of large molecules across
the BBB, but in most cases, the level of transcytosis has been
modest, and there has been limited understanding of the deter-
minants of effective transport (Wang et al., 2013; Yu et al., 2011;
Staquicini et al., 2011; Sumbria et al., 2013). Although recent
studies focused on the effect of antibody affinity to the efficiency
of transport (Yu et al., 2011), we explored the hypothesis that
monovalent versus bivalent engagement of the TfR may be a
much more important determinant of transport efficiency.
Consistent with this hypothesis, our experiments show that the
binding mode to the TfR is absolutely crucial for successful
transport of antibodies across the BBB. We also find that
increased brain exposure is associated with a considerable
increase in potency for a therapeutic antibody in a chronic model
of Alzheimer’s disease (Figure 6). Our findings imply significantly
improved treatment options for early disease modification in
preclinical Alzheimer’s disease in general and, in particular, in
ApoE4 gene carriers being at higher risk of developing
Alzheimer’s disease (Mielke et al., 2012). The difference in brain
exposure between a bivalent and monovalent binding mode is
striking. Our imaging experiments show extensive uptake of
both sFab and dFab construct in brain capillaries within minutesentifies the Brain Shuttle Constructs within BECs at the BBB
l (podocalyxin; green) and the abluminal (collagen IV; magenta) sides of the
d line is cross-section line for the image in (B).
es the BEC intracellular space.
ruct (red) 15 min postinjection shows the construct within vesicular structures
5min (D and F) and 8 hr (E andG) postinjection is shown. (D)–(G) were acquired
brane (podocalyxin) in green.
ls 8 hr postinjection. (K) Merged image shows costaining at basal lamina (arrow)
ostinjection. (O) Merge image shows intracellular staining of dFab (arrows).
ing to the degradation pathway in vivo. XYZ stack of the boxed area shows that
.







Figure 5. Brain Exposure and Plaque Deco-
ration after i.v. Administration
(A) mAb31 (10 mg/kg), dFab (16.7 mg/kg), and
sFab (13.3 mg/kg) constructs were i.v. injected in
PS2APP transgenic animals at equimolar con-
centrations, and animals were perfused and
sacrificed 8 hr postinjection. No significant
increase in plaque decoration was detected for the
dFab compared tomAb31. For the sFab construct,
a 55-fold higher plaque decoration was detected
than the parent mAb31 based on fluorescence
intensity at 555 nm from the detection antibody.
(B–D) Representative immunohistochemistry
staining in the cortex of mAb31 (B), dFab (C), and
sFab (D) 8 hr postinjection is shown. The
dFab shows only microvessel staining, whereas
the sFab decorates the b-amyloid plaques
extensively.
(E) Graph shows that a low dose of the sFab
construct (green, 2.66 mg/kg) rapidly and signifi-
cantly reaches the plaques in the brain compared
to both 2 mg/kg (blue) and 10 mg/kg (light blue)
of mAb31. The target engagement of the
sFab construct is sustained over at least 1 week
postinjection.
(F and G) Immunohistochemistry staining shows
plaque decoration for mAb31 at 2 mg/kg (F) and
sFab at 2.66 mg/kg (G) 7 days postinjection.
(H) Simplified model illustrates the difference in
intracellular sorting of Tf, sFab, and dFab. Both Tf
and sFab are able to cross the BECs by preserving
TfR’s natural intracellular trafficking. In contrast,
dFab induces an abnormal configuration of TfR
leading to lysosomal sorting and degradation.
Data are presented as mean ± SD. See also
Figure S4.
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diverges after that. Whereas the sFab construct exits the capil-
laries, enters the CNS compartment, and efficiently engages
the target, the dFab constructs remain within BECs and become
colocalized with lysosomal markers, suggesting sorting into a
degradation pathway.
The precise mechanism by which the sFab construct
escapes lysosomal sorting and is released on the abluminal
side is not known. It could be that the sFab construct simply
docks as an additional ligand onto the TfR adjacent to trans-
ferrin without changing the way the receptor complex is recog-
nized by the intracellular-sorting machinery. Thus, sFab
constructs may efficiently use the endogenous transcytosis
mechanism to get across the BECs. In contrast, the dFab con-
structs may induce substantial dimerization of the TfR, followed56 Neuron 81, 49–60, January 8, 2014 ª2014 Elsevier Inc.by internalization and sorting to a lyso-
somal pathway. This could potentially
be prevented using a low-affinity dFab
variant to reduce dimerization of TfR on
the cell surface or inside specific organ-
elles. Different subpopulations of TfR-
containing early endosomes have been
described, raising the possibility that
different internalization mechanismscould deliver cargo into different subsets of early endosomes
(Navaroli et al., 2012). Local clustering of TfR on the cell surface
using multivalent streptavidin increases the rate of endocytosis
primarily due to enhanced clathrin-coated pit initiation (Liu
et al., 2010). Pre-early endosome sorting has been shown to
begin at the plasma membrane (Lakadamyali et al., 2006).
Under these conditions, dynamic endosomes could be formed
leading to degradation of the cargo, which may be the mecha-
nism that targets dFab constructs to the lysosome. Whether
these different modes of internalization are involved in discrim-
ination between the sFab and dFab needs to be further investi-
gated, but our data strongly suggest that differences in TfR
binding mode lead to major differences in intracellular sorting,
which ultimately allows sFab-associated cargos to cross
the BBB.





(legend on next page)
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significant effect on receptor function. As shown in Figure 2, pro-
longed in vivo exposure with a bivalent, and likely also with a
multivalent, construct can lead to downregulation of cell surface
TfR, which might impact the survival of cell populations relying
on iron uptake, e.g., erythrocyte precursors. TfR is involved in
regulation of iron homeostasis associated with adult neurode-
generation (LaVaute et al., 2001), and TfR knockout mice show
defects in nervous and hematopoietic systems (Levy et al.,
1999). Thus, the design of novel Brain Shuttle constructs should
start with an understanding of the underlying BBB receptor
biology in order to generate variants that are both efficient in
crossing the BBB and have an acceptable safety profile. Our
Brain Shuttle design with a sFab fragment fused to the
C-terminal end of the Fc domain preserves the normal IgG struc-
ture of the therapeutic antibody while greatly increasing the
delivery of the antibody to the brain parenchyma. Such a Brain
Shuttle design could be expanded to other cargos, such as
therapeutic growth factors, enzymes, and peptides, and could
greatly facilitate the development of a new generation of bio-
therapeutics for brain disorders.
EXPERIMENTAL PROCEDURES
Engineering of Brain Shuttle Constructs
Brain shuttle constructs were engineered by fusing a sc Fab fragment of an
antibody against the mTfR raised in rats to the C terminus of the heavy chain
of an antibody against Ab (mAb31). Although mAb31 is a humanized antibody,
the sc Fab fragment contained human constant and rat variable regions, con-
nected by a glycine-serine linker. In the case of the monovalent construct,
knobs-into-holes technology was used to favor heterodimeric pairing of one
mAb31 heavy chain carrying the mTfR antibody fragment to a ‘‘free’’ heavy
chain. For the in vitro transcytosis assay, an antibody against the human TfR
was generated either as a standard IgG or in a ‘‘one-armed’’ IgG format using
knobs-into-holes.
Immunohistochemistry, Immunocytochemistry, Image Processing,
and Quantification
All animal studies were performed according to Roche animal license.
Six-month-old PS2APP transgenic mice were i.v. injected with sFab or dFab-
mAb31 constructs (10 mg/kg). At 15 min or 8 hr postinjection, animals were
anesthetized, transcardially perfusedwith 13PBS, followedby 2%paraformal-
dehyde. The perfused brains were soaked in 2% paraformaldehyde for 7 hr
before sectioning. After inclusion in agarose, brains were cut using a Leica
VT1000M vibratome at 100 mm in the sagittal plane. Sections were stored
at 20C in 13 PBS/glycerol (1/1). For the immunostaining, sections were
rinsed three times for 5 min in 13 PBS at room temperature and preincubated
for 1 hr in antibody-blocking buffer that is 10% donkey serum in PBST (13
PBS with 0.3% Triton X-100). All rinses between incubation steps were with
PBS. After rinsing, processed sections were incubated with different primaryFigure 6. In Vivo Efficacy in a Chronic Study in Plaque-Bearing PS2AP
Target plaque binding of administrated constructs bound to residual plaques at t
sFab and middose sFab (A–D, respectively). Clear dose-dependent target occup
representative animals from baseline (E), vehicle (F), middose mAb31 (G), and
treatment with middose sFab (H).
(I) Quantitative morphometric analysis after immunohistochemical staining of pla
sacrificed at an age of 4.5 months is shown as baseline level of amyloidosis at th
treatment with middose sFab compared to the progressive plaque formation seen
at the low-dose sFab. Thus, sFab construct significantly reduces plaque numbe
(J) Analysis of plaque sizes revealed reduction of plaque numbers most pronoun
Data are presented as mean ± SD. *p% 0.05, **p% 0.01, and ***p% 0.001. Se
58 Neuron 81, 49–60, January 8, 2014 ª2014 Elsevier Inc.antibodies against collagen IV (Serotec; 1:100), Lamp-2 (Fitzgerald; 1:100),
and podocalyxin (R&D Systems; 1:100) overnight in antibody-blocking buffer
at 4C. After three 10 min washes in 13 PBS at room temperature, sections
were incubated with a donkey anti-rat, donkey anti-rabbit, and/or a goat anti-
human secondary antibody conjugated to Alexa 488, 555, or 647 (Molecular
Probes) for 2 hr at room temperature. All incubations were done under gentle
agitation. After an intensive rinse with 13 PBS, sections were stained with
DAPI, mounted with Dako Fluorescent Mounting Medium on glass slides, and
a 0.17 mm coverslip was applied. Images were acquired using a Leica TCS
SP5 confocal system using a HCX PL APO CS 403 1.3 oil UV or a HCX PL
APO LB 633 1.4 oil UV objective. A zoom could have been used for some
images. Deconvolution of confocal images was done using the Leica LAS-AF
3D Deconvolution tool. Imaris software was used to merge images, to perform
3D reconstruction, cross-sections, and movies. To quantify the fluorescence
intensity corresponding to sFab or dFab constructs containedwithin themicro-
vessels, we performed reconstruction of the microvessel network by recording
at least 230 single optical layers (step size of 0.17 mm) with a HCX PL APO CS
403 1.3 oil UV objective, at a 5123 512-pixel resolution. The 15 min time point
dFab sample was used to define optimal confocal settings with such settings
used for the acquisition of all subsequent z stacks. Imaris software was used
to reconstruct 3D images and to quantify the fluorescent signal contained in
the microvessels by generating an Isosurface (default parameters including
threshold of 25 for all images). All parameters were kept constant to allow
comparative measurements between images. Three brain sections per condi-
tion were recorded with at least 600 mm of microvessels quantified per image.
The fluorescence intensity/mmwascalculatedbydividing the total fluorescence
intensity by the total length of microvessels measured. The average was calcu-
lated with Microsoft Excel, and statistical analysis (one-way ANOVA with
Bonferroni’s multiple comparison test) was performed using Prism.
For immunocytochemistry, bEnd3 cells seeded on 0.17 mm coverslips were
carefully washed with warm PBS followed by a 10 min fixation with 3% para-
formaldehyde. Coverslips were rinsed three times in 13 PBS at room temper-
ature, preincubated for 5min in PBST, followed by 30min in 5% donkey serum
in PBS. Primary and secondary antibodies are similar to those mentioned
above. DAPI was used to label nuclei. Confocal scans were performed from
the top to the bottom of the cell nucleus using a HCX PL APO CS 203 0.7
dry UV objective or a HCX PL APO LB 633 1.4 oil UV objective with a zoom
of three, at a resolution of 5123 512 pixels. dFab sample was used to establish
the optimal confocal settings with such settings used for the acquisition of all
subsequent z stacks (step size, 0.25 mm). Colocalization analysis was
performed using the Imaris Colocalization tool. Briefly, confocal files were
opened in Imaris, and the colocalization tool was activated with sFab or
dFab as Channel A and Lamp-2 as Channel B. A threshold of 25 was used
for both channels on all images. After building a colocalization channel, the
percentage of lysosomes containing the sFab or dFab construct was obtained
using the following value: percentage (%) of volume B above threshold colo-
calized = (NColoc/NObjectB) 3 100. In total, three experiments with at least
ten cells quantified per experiment were performed for each condition. The
average was calculated with Microsoft Excel, and statistical analysis (one-
way ANOVA with Bonferroni’s multiple comparison test) was done in Prism.
Imaging and Quantification of Plaque Load
Fresh frozen brains from PBS-perfused animals were sagittal sectioned with a
cryostat (CM3050S; Leica BioSystems) and processed for further analysis byP Mice Treated by 14 Weekly i.v. Injections
he end of the study is shown for low-dose mAb31, middose mAb31, low-dose
ancy is seen for sFab (C and D). Histological plaque distribution is shown for
middose sFab (H) groups. Reduction of plaques is clearly appreciable after
ques is shown for cortex and hippocampus. Plaque load of untreated animals
e start of the study. A significant reduction in plaque numbers is evident after
in vehicle-treated animals; a trend of reduced plaque formation appears even
rs in both cortex and hippocampus.
ced for small plaque sizes.
e also Figures S7 and S8.
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previously (Bohrmann et al., 2012) with some modifications. In this study,
quantification of the plaque number in APPSwe/presenilin mice was obtained
from six sections per mouse within the hippocampal formation and cortex and
cut at a nominal thickness of 10 mm. After staining of sections with mAb31 at
2 mg/ml for 1 hr at room temperature and detection by affinity-purified goat
anti-human IgG (H + L) conjugated to Alexa 555 at 20 mg/ml for 1 hr at room
temperature (#A21433; Molecular Probes ), virtual slides with a resolution of
0.645 mm/pixel were obtained with a Metafer4 slide scanner (MetaSystems).
Quantitative image analysis was done by a customized rule set developed
in-house for the automated detection of stained amyloid plaques after interac-
tive selection within most affected brain regions using the Definiens XD 2.0
software package. Calculations were made with common spreadsheet
software (Microsoft Excel). Statistical evaluation was done using a two-tailed
Student’s t test.
Flow Cytometry
For the intra- and extracellular TfR detection, bEnd3 cells were stained with an
anti-CD71-Alexa 647 (YTA74.4) (AbD Serotec) or the IgG2a-Alexa 647 (G155-
178) (BD PharMingen) isotype control. A goat-anti-human-Alexa 555 (Life
Technologies) was used for the detection of the dFab and sFab constructs.
A total of 1 3 106 cells was incubated for 1 hr at 4C with the antibodies and
washed twice with the staining buffer (BD PharMingen). For the intracellular
staining, the cells were fixed (BD Cytofix) at 4C for 30 min, permeabilized
(BD Perm Buffer III) on ice for 30 min, and incubated with each antibody at
4C for 1 hr. After staining, the cells were analyzed using a Guava easyCyte
flow cytometer (Millipore).
In Vitro Transcytosis Assay
Medium and supplements for hCMEC/D3 (see Weksler et al., 2005) were
obtained from Lonza. hCMEC/D3 cells (passages 26–29) were cultured to
confluence in EBM2 medium containing 2.5% FBS, a quarter of the supplied
growth factors, and fully complemented with supplied hydrocortisone,
gentamycin, and ascorbic acid. For all transcytosis assays, high-density
pore (1 3 108 pores/cm2) PET membrane filter inserts (0.4 mm pore size,
12 mm diameter) were used in 12-well cell culture plates. The content of anti-
body in the samples was quantified using a highly sensitive IgG ELISA.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
eight figures, and one movie and can be found with this article online at
http://dx.doi.org/10.1016/j.neuron.2013.10.061.
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